Maravai LifeSciences Cuts Ribbon on New Headquarters

New Facility for Maravai’s TriLink BioTechnologies Set to Supercharge messengerRNA Therapeutics Development

SAN DIEGO (November 21, 2019) – Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, officially unveiled its new headquarters yesterday, with local officials on hand to proclaim November 20 “mRNA Day” in San Diego. In addition to doubling overall manufacturing capacity, TriLink BioTechnologies, a Maravai LifeSciences company whose headquarters will also be housed in the new facility, has added five new Current Good Manufacturing Practice (cGMP) suites, for a total of six, that can be specifically tailored for customer drug development campaigns including scaleup for Phase I clinical trials.

Messenger RNA (mRNA) therapeutics are among the most promising areas in disease treatment, research and development. The rapid growth in mRNA research and clinical trials has resulted in a critical shortage of synthetic mRNA production capacity. A leader in the field, TriLink is particularly recognized for its proprietary CleanCap® technology for co-transcriptional capping of mRNAs, an important step in the production of synthetic mRNA, one of TriLink’s core products.

The new 95,000-square-foot facility houses the company’s current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees.

“This new facility and related investments we are making in the business help us in the race to fill demands for mRNA, an important building block in current therapeutic research,” said Brian Neel, chief operating officer for TriLink. “We can now further scale up our chemistry and biological operations for gene editing and DNA/RNA therapeutics and diagnostics.”

About TriLink BioTechnologies

Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of DNA and RNA for research, diagnostics, therapeutics and OEM customers. Specializing in the manufacture of highly modified nucleic acids such as mRNA and custom oligonucleotides, TriLink products are instrumental in the fields of gene and oligonucleotide therapy, gene editing and diagnostics. The company is ISO 9001:2015 certified and operates cGMP suites for manufacturing. TriLink is headquartered in San Diego, where it also maintains its manufacturing facilities. The company was acquired by Maravai LifeSciences in 2016.

About Maravai LifeSciences

Maravai LifeSciences companies provide reagents and services to life science researchers and commercial partners to enable breakthrough discoveries and improvements in human health. Maravai’s products are used broadly by academic researchers investigating cancer and other diseases, firms developing new genetic therapies, biopharmaceutical partners validating and monitoring manufacturing processes and by OEM partners who incorporate Maravai offerings into their own products. The Maravai portfolio focuses on bioprocess impurity testing, oligonucleotide synthesis and protein detection. Maravai is a portfolio company of GTCR, a leading private equity firm focused on investing in growth companies in healthcare, technology and information services and financial services.

 

Back to news